Galderma Differen adapalene gel Rx acne treatment planned to compete with Retin-A.
This article was originally published in The Tan Sheet
GALDERMA HAS NDA PENDING FOR Rx DIFFEREN (ADAPALENE .1%) ACNE GEL, a naphtholic acid derivative that has "potent retinoid and anti- inflammatory properties," according to Ft. Worth, Tex.-based Galderma Labs. Once approved, Differen will compete with Ortho Pharmaceutical's prescription acne treatment, Retin-A.
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC